Brief: Active Biotech says CONCERTO trial of Laquinimod in RRMS did not meet primary endpoint
08/05/2017 06:45
STOCKHOLM, May 8 (Reuters) - Active Biotech ACTI.ST :
* Teva and Active Biotech today announced results from the
CONCERTO trial in patients with relapsing-remitting
multiple sclerosis (RRMS)
* Says primary endpoint in CONCERTO -- the evaluation
of laquinimod versus placebo to evaluate the time to Confirmed
Disability Progression (CDP) after at least 3 months - was not
met
(Reporting by Stockholm Newsroom)